Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis

AIM: To evaluate and compare the anatomical functional outcomes negative effects of three anti-vascular endothelial growth factor (VEGF) drugs in treatment macular edema (ME) due to retinal vein occlusion (RVO) based on evidence pooled from current clinical trials observational studies. METHODS: A systematic literature search was conducted nine online databases inception until April 30, 2022. The main endpoints were best corrected visual acuity (BCVA), central thickness (CMT), adverse events (AEs). Cumulative Meta-analysis synthesize drugs. retrieved data analyzed using Stata software (version 12.0). RESULTS: total 20 studies comprising 1674 eyes met inclusion criteria Meta-analysis. It observed that conbercept aflibercept had better compared with ranibizumab at 1mo [weight mean difference (WMD)=-0.03, P=0.001; WMD=-0.05, P=0.019], but not different 6mo. Moreover, there statistically significant proportion patients gaining ≥15 letters 12-24mo between [odds ratio (OR)=1.16, P=0.427]. Conbercept higher CMT change (WMD= -14.43, P=0.014) 6mo (WMD=-35.63, P≤0.001) ranibizumab. Meanwhile, (WMD=-10.14, P=0.170), (WMD=-26.98, P=0.140) (WMD=-12.34, P=0.071) comparable among groups. Similarly, AEs significantly treatments (OR=0.75, P=0.305; OR=1.04, P=0.89). stability effect size BCVA improved increase sample size. Aflibercept required fewer injections CONCLUSION: This is first study efficacy intravitreal administration conbercept, ranibizumab, RVO-ME. Intravitreal or results vision reduction can be considered a promising innovative drug good anti-VEGF effects.